Since the current standard of care in patients with unresectable or relapsing metastatic ccRCC relies on antiangiogenic therapy with tyrosine kinase inhibitors and immunotherapy with checkpoint inhibitors [11], it is possible that PSMA-targeting radiopharmaceuticals might be able to assess and predict treatment response. This evidence concerns the gene FOLH1 and nonpapillary renal cell carcinoma.